Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aphios, a biotechnology company, has received a Japanese patent for an improved method of inactivating viruses and other pathogens in biologics such as monoclonal antibodies, recombinant therapeutics, human plasma and plasma proteins.
Subscribe to our email newsletter
The Aphios method is purely physical and does not utilize organic solvents, heat, irradiation, and/or chemicals commonly used in commercially available virus inactivation techniques, the company said. As such, therapeutic proteins and enzymes retain structural and biological integrity, and products are left without traces of denaturing solvents or potentially mutagenic chemicals, the company noted.
According to Aphios, the method utilizes supercritical, critical, or near-critical fluids with or without cosolvents (SuperFluids or SFS). SuperFluids are normally gases which, when compressed, exhibit enhanced solvation, penetration and expansion properties.
Dr Castor, lead inventor of this technology, said: “With a uniquely physical mechanism of action, critical fluid inactivation can be used as an orthogonal method with other virus inactivation techniques to eliminate emerging viruses and other unknown pathogens from biologics and human plasma.”